Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor


Abbott logoAbbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitor is now available to Medicare patients, after the Centers for Medicare & Medicaid Services determined that the device can be classified as a therapeutic CGM.

The FreeStyle Libre is designed to read glucose levels through a sensor worn on the back of a person’s upper arm for up to 10 days. Abbott touted that its device is the only CGM covered by Medicare that doesn’t require user calibration.

Get the full story at our sister site, Drug Delivery Business News.


Hear from top executives at Abbott, Google, Boston Scientific, Medtronic and more at DeviceTalks Minnesota, June 4–5 in St. Paul.

Speak Your Mind